GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Equity-to-Asset

Renalytix (Renalytix) Equity-to-Asset : -1.27 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Renalytix's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-11.11 Mil. Renalytix's Total Assets for the quarter that ended in Mar. 2024 was $8.77 Mil. Therefore, Renalytix's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was -1.27.

The historical rank and industry rank for Renalytix's Equity-to-Asset or its related term are showing as below:

RNLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.4   Med: 0.75   Max: 0.98
Current: -1.27

During the past 6 years, the highest Equity to Asset Ratio of Renalytix was 0.98. The lowest was -4.40. And the median was 0.75.

RNLX's Equity-to-Asset is ranked worse than
94.98% of 677 companies
in the Healthcare Providers & Services industry
Industry Median: 0.46 vs RNLX: -1.27

Renalytix Equity-to-Asset Historical Data

The historical data trend for Renalytix's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Equity-to-Asset Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial 0.88 0.87 0.93 0.61 0.23

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.23 -0.08 0.12 -1.27

Competitive Comparison of Renalytix's Equity-to-Asset

For the Health Information Services subindustry, Renalytix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Equity-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Renalytix's Equity-to-Asset falls into.



Renalytix Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Renalytix's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=6.967/30.629
=0.23

Renalytix's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=-11.111/8.769
=-1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (NAS:RNLX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Renalytix Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Renalytix's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE